Last reviewed · How we verify
Scilex Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
1 Phase 3
1 Phase 2
4 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| ZTlido | ZTlido | marketed | ||||
| Lidocaine patch 1.8% | Lidocaine patch 1.8% | marketed | Local anesthetic | Voltage-gated sodium channels | Pain management | |
| SP-102 | SP-102 | phase 3 | cannabinoid | CB1 receptor | Pain |
Therapeutic area mix
- Pain · 1
- Pain management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ain Shams Maternity Hospital · 1 shared drug class
- Ain Shams University · 1 shared drug class
- Aligarh Muslim University · 1 shared drug class
- Aphios · 1 shared drug class
- Atlantic Health System · 1 shared drug class
- Aultman Health Foundation · 1 shared drug class
- Azienda Ospedaliera Universitaria Policlinico "G. Martino" · 1 shared drug class
- Abant Izzet Baysal University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Scilex Pharmaceuticals, Inc.:
- Scilex Pharmaceuticals, Inc. pipeline updates — RSS
- Scilex Pharmaceuticals, Inc. pipeline updates — Atom
- Scilex Pharmaceuticals, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Scilex Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/scilex-pharmaceuticals-inc. Accessed 2026-05-16.